Immunocore Holdings

Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Earnings data Q4 2020

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Immunocore (IMCR) Might Surprise This Earnings Season

The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to a 29.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 30% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Here's What You Should Know

Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in Immunocore Holdings PLC Sponsored ADR (IMCR): Can Its 10.2% Jump Turn into More Strength?

The consensus price target hints at a 60.4% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Immunocore Holdings PLC Sponsored ADR (IMCR) Could Rally 60%: Here's is How to Trade

Immunocore Holdings plc has one asset already in the market. It has a pipeline of TCR bispecific molecules targeting various indications.

Immunocore: Attractive Commercial-Stage Biopharma

Agenus

CureVac B.V

Dynavax Technologies

New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.

Bet on These 4 Biotech Stocks With Bright Prospects

Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress

The consensus price target hints at a 44.9% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Immunocore Holdings PLC Sponsored ADR (IMCR) Have the Potential to Rally 45% as Wall Street Analysts Expect?

Immunocore Holdings PLC Sponsored ADR (IMCR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here's Why Momentum in Immunocore Holdings PLC Sponsored ADR (IMCR) Should Keep going

Does Immunocore Holdings PLC Sponsored ADR (IMCR) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Immunocore Holdings PLC Sponsored ADR (IMCR) a Strong Momentum Stock: Buy Now?

The consensus price target hints at a 31.8% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Immunocore Holdings PLC Sponsored ADR (IMCR) Could Surge 32%: Read This Before Placing a Bet

Immunocore Holdings PLC Sponsored ADR (IMCR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Here's Why "Trend" Investors Would Love Betting on Immunocore Holdings PLC Sponsored ADR (IMCR)

Immunocore Holdings (NASDAQ:IMCR ) Q2 2022 Earnings Conference Call August 9, 2022 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO & Director Brian Di Donato - CFO & Head, Strategy Ralph Torbay - Head, Commercial David Berman - Head, Research & Development Conference Call Participants Michael Yee - Jefferies Jessica Fye - JPMorgan Chase & Co. Tyler Van Buren - Cowen and Company Justin Kim - Oppenheimer Justin Zelin - BTIG Matthew Phipps - William Blair & Company Gil Blum - Needham & Company Patrick Trucchio - H.C. Wainwright & Co. Operator Greetings.

Immunocore Holdings (IMCR) CEO Bahija Jallal on Q2 2022 Results - Earnings Call Transcript

Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update

Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022

Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Jazz Pharmaceuticals (JAZZ) have performed compared to their sector so far this year.

Is Immunocore (IMCR) Outperforming Other Medical Stocks This Year?

Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC ® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

Alliance Resource Partners

Ardmore Shipping

Franklin Covey

 StoneX Group

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, FC, ASC, SNEX and ARLP.

5 Stocks With Recent Price Strength to Gain From July Rally

The consensus price target hints at a 29.4% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Immunocore Holdings PLC Sponsored ADR (IMCR) Could Surge 29%: Read This Before Placing a Bet

100% technical buy signals. 13 new highs and up 38.33% in the last month.

Immunocore - Healthcare Biotech

Immunocore Announces $140 Million Private Placement Financing

Axsome Therapeutics

Takeda Pharmaceutical

Immunocore, Axsome Therapeutics, and Takeda are significantly outperforming the market this year.

What's Winning in 2022? 3 Stocks That Are Doing Fine

Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV

Here's Why Immunocore Holdings PLC Sponsored ADR (IMCR) is a Great Momentum Stock to Buy

The consensus price target hints at a 35.9% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

News for Immunocore Holdings Stock (IMCR)